Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025Journal of Antimicrobial Chemotherapy

Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTingting WuQDQin DingSHShuqi Huang

Discussion

Loading...

Member takes

Overview

Population pharmacokinetics model reveals AKI risk factors in critically ill patients, suggesting tailored dosing.

Key Points

  • Higher exposure to ceftazidime–avibactam correlates with acute kidney injury risk, emphasizing the need for careful dosing adjustments.
  • Ceftazidime AUCss,24 h and mechanical ventilation identified as significant risk factors for acute kidney injury in patients.
  • Population pharmacokinetics and time-to-event analysis were utilized to optimize individual treatment strategies for critically ill patients.
  • Optimized dosing recommendations are crucial for balancing efficacy and safety in patients with varying renal functions.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/68c235ccb210217d64771cafhttps://doi.org/10.1093/jac/dkaf275
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacokinetics/Pharmacodynamics and Therapeutic Drug Monitoring of Ceftazidime/Avibactam in Patients With Gram‐Negative Bacterial Infections2025
  2. 2PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno–venous hemofiltration2025
  3. 3Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design2025
  4. 4Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration2025
  5. 5Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study2025